Engineering radiolabeled antibody fragments for enhanced tumor to kidney ratio
Project/Area Number |
25713045
|
Research Category |
Grant-in-Aid for Young Scientists (A)
|
Allocation Type | Partial Multi-year Fund |
Research Field |
Radiation science
|
Research Institution | Chiba University |
Principal Investigator |
Uehara Tomoya 千葉大学, 薬学研究科(研究院), 准教授 (10323403)
|
Co-Investigator(Renkei-kenkyūsha) |
HANAOKA Hirofumi 群馬大学, 大学院医学研究科, 准教授 (50361390)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥25,090,000 (Direct Cost: ¥19,300,000、Indirect Cost: ¥5,790,000)
Fiscal Year 2015: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2014: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2013: ¥12,350,000 (Direct Cost: ¥9,500,000、Indirect Cost: ¥2,850,000)
|
Keywords | PET / 治療 / 腎臓 / 標識薬剤 / SPECT / ガリウム / 内照射治療 |
Outline of Final Research Achievements |
The renal localization of radiolabeled antibody fragments is a limitation of clear target imaging and radiothearpy. Herein, we describe a strategy using a 67Ga-labeling reagent for antibody fragments that liberates 67Ga-NOTA-Methionine (NOTA-Met) by the action of renal brush border enzymes to reduce renal radioactivity levels. A 67Ga-labeled Fab fragments of anti-c-kit IgG using this labeling agentl resulted in significantly lower renal radioactivity levels and clearer tumor images than those of 67Ga-labeled Fabs using conventional methods. This strategy and radiolabeling reagent would also be applicable for engineered antibody fragments and also considerable influence on the development of new diagnostic and therapeutic engineered antibody fragments.
|
Report
(4 results)
Research Products
(9 results)